Feasability Study on the Use of Botulinum Toxin A in Primary Adductor Tendinopathies Refractory to Medical Treatment

Trial Profile

Feasability Study on the Use of Botulinum Toxin A in Primary Adductor Tendinopathies Refractory to Medical Treatment

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Acronyms PETRA
  • Most Recent Events

    • 19 Jul 2018 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020.
    • 19 Jul 2018 Planned primary completion date changed from 1 Aug 2019 to 1 Nov 2019.
    • 19 Jul 2018 Planned initiation date changed from 1 May 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top